These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 31199580

  • 1. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
    Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.
    Cancer Med; 2019 Aug; 8(9):4330-4337. PubMed ID: 31199580
    [Abstract] [Full Text] [Related]

  • 2. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Pan Y, Yuan C, Cheng C, Zhang Y, Ma Y, Zheng D, Zheng S, Li Y, Jin Y, Sun Y, Chen H.
    Int J Cancer; 2019 Jan 15; 144(2):290-296. PubMed ID: 30230541
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S.
    BMC Cancer; 2020 Jan 31; 20(1):83. PubMed ID: 32005111
    [Abstract] [Full Text] [Related]

  • 5. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX, Chen ZH, Jie GL, Wang Z, Yan HH, Wu SP, Zhang SL, Lu DX, Zhang XC, Wu YL.
    Cancer Med; 2023 Jan 31; 12(1):396-406. PubMed ID: 35702826
    [Abstract] [Full Text] [Related]

  • 6. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
    Bowman L, Tiu R, Smyth EN, Willard MD, Li L, Beyrer J, Han Y, Singh A.
    Clin Lung Cancer; 2021 Jan 31; 22(1):32-41.e1. PubMed ID: 33221173
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ, Carbone DP, D'Souza DM, Shilo K, Abdel-Rasoul M, Zhao W, Williams TM, Jones D, Merritt RE.
    Lung Cancer; 2020 May 31; 143():60-66. PubMed ID: 32208298
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J, Liu Y.
    Pathol Res Pract; 2020 Feb 31; 216(2):152797. PubMed ID: 31926773
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
    Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M.
    Lung Cancer; 2019 Dec 31; 138():43-51. PubMed ID: 31634654
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, Kim HR, Cho BC, Korean Lung Cancer Consortium (KLCC).
    PLoS One; 2019 Dec 31; 14(11):e0224379. PubMed ID: 31765373
    [Abstract] [Full Text] [Related]

  • 19. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
    Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M.
    Clin Cancer Res; 2015 Apr 15; 21(8):1935-43. PubMed ID: 25351745
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.